{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:52:13Z","timestamp":1790254333719,"version":"4.1.0"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:p>Although anti\u2013tumor necrosis factor (anti-TNF) antibodies are associated with a clear risk of agranulocytosis in adults and are known to cross the placenta, monitoring of the absolute neutrophil count (ANC) in neonates born to mothers receiving these biological agents is not currently recommended. Here, we report on the first case series of 4 newborn patients with severe neutropenia born to mothers treated for ulcerative colitis with infliximab during pregnancy (including the third trimester). The newborns presented with severe neutropenia at birth, which was subsequently complicated by skin infections. The newborns' ANCs returned to the normal range within 8 to 14 weeks, at which time infliximab could not be detected in the blood. Anti-TNF agents probably exert a direct, toxic effect on the bone marrow. Furthermore, the detection of a CD16 autoantibody in 1 mother-newborn pair suggests that infliximab can induce autoimmune neutropenia. Abnormally high levels of the CD16 autoantibody in newborn serum or immaturity of the fetal bone marrow might explain why neutropenia was observed in the child but not in the mother. We recommend the systematic measurement of ANC on cord blood at birth and (in the event of an infection) in the weeks thereafter.<\/jats:p>","DOI":"10.1542\/peds.2014-0054","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T04:24:19Z","timestamp":1412051059000},"page":"e1189-e1193","source":"Crossref","is-referenced-by-count":52,"title":["Anti\u2013TNF-\u03b1 Therapy May Cause Neonatal Neutropenia"],"prefix":"10.1542","volume":"134","author":[{"given":"Tamazoust","family":"Guiddir","sequence":"first","affiliation":[{"name":"Service de P\u00e9diatrie, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tewfik Bibi","family":"Triki","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019H\u00e9matologie, Universit\u00e9 Paris 13, Sorbonne Paris Cit\u00e9, H\u00f4pital Jean Verdier, Assistance Publique des H\u00f4pitaux de Paris, Bondy Cedex, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Candon","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019Immunologie, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, H\u00f4pital Necker, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Croisille","sequence":"additional","affiliation":[{"name":"Etablissement Fran\u00e7ais du Sang, Cr\u00e9teil, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie P\u00e9diatrique, H\u00f4pital Robert Debr\u00e9, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"de Pontual","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"issue":"9317","key":"2021120906525243200_B1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"587","key":"2021120906525243200_B2","first-page":"58","article-title":"Current dilemmas in the management of inflammatory bowel disease.","author":"Rutgeerts","year":"2002","journal-title":"Eur J Surg Suppl"},{"key":"2021120906525243200_B3"},{"issue":"23","key":"2021120906525243200_B4","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120906525243200_B5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.","volume":"36","author":"Bessissow","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2021120906525243200_B6"},{"issue":"2","key":"2021120906525243200_B7","first-page":"247","article-title":"Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.","volume":"23","author":"Favalli","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"19","key":"2021120906525243200_B8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"2021120906525243200_B9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2009.09.009","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: special situations.","volume":"4","author":"Van Assche","year":"2010","journal-title":"J Crohn's Colitis"},{"issue":"1","key":"2021120906525243200_B10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy.","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2021120906525243200_B11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2021120906525243200_B12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease.","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2021120906525243200_B13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature.","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2021120906525243200_B14","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by fas ligand.","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2021120906525243200_B15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H","article-title":"CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty\u2019s and large granular lymphocyte syndromes.","volume":"43","author":"Coakley","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2021120906525243200_B16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0889-857X(05)70211-8","article-title":"Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis.","volume":"27","author":"Keystone","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"2021120906525243200_B17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.crohns.2012.01.014","article-title":"Anti-TNF therapy induced immune neutropenia in Crohn\u2019s disease: report of 2 cases and review of literature.","volume":"6","author":"Sebastian","year":"2012","journal-title":"J Crohn's Colitis"},{"issue":"4","key":"2021120906525243200_B18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2007.07.019","article-title":"Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from northern California.","volume":"133","author":"Mahadevan","year":"2007","journal-title":"Gastroenterology"},{"issue":"12","key":"2021120906525243200_B19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis.","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2021120906525243200_B20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2021120906525243200_B21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2021120906525243200_B22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn\u2019s disease before and after delivery.","volume":"43","author":"Kane","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"2021120906525243200_B23","first-page":"555","year":"2011"},{"key":"2021120906525243200_B24","year":"2011"},{"key":"2021120906525243200_B25","year":"2010"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e1189\/1099895\/peds_2014-0054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e1189\/1099895\/peds_2014-0054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:12:30Z","timestamp":1639098750000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/134\/4\/e1189\/32998\/Anti-TNF-Therapy-May-Cause-Neonatal-Neutropenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-0054","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}